Triomics completes $220 million Series B financing

According to TechCrunch, AI medical technology company Triomics has completed a Series B funding of $220 million, led by Battery Ventures and with participation from existing shareholders such as Nexus Venture Partners, Lightspeed, and Y Combinator. The company was founded in 2021 and completed a $15 million Series A financing in mid-2024. Triomics initially focused on clinical trial matching, but later expanded its platform functionality by adding patient summary features to help doctors efficiently obtain key information.